There are 2789 resources available
1080P - HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program
Presenter: Jean Jacques Grob
Session: ePoster Display
1081P - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Presenter: Jesper Breeschoten
Session: ePoster Display
1082P - Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Presenter: Filip Janku
Session: ePoster Display
1083P - A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Presenter: Alexander Shoushtari
Session: ePoster Display
1042P - Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
Presenter: Ines Pires da Silva
Session: ePoster Display
1043P - NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1044P - Sequential targeted and immunotherapies in stage IV melanoma
Presenter: Teresa Amaral
Session: ePoster Display
1045P - Comparison between first-line target therapy and immunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients
Presenter: Riccardo Marconcini
Session: ePoster Display
1046P - First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
Presenter: Yasuhiro Nakamura
Session: ePoster Display
1047P - Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
Presenter: Prachi Bhave
Session: ePoster Display